Bayer Maintains Financial Outlook Amid US Tariff Uncertainty

Bayer reaffirms 2026 EBITDA guidance, citing existing trade pacts, as Goldman Sachs reduces its stake. Shares trade below 50-day average but show long-term gains.

While the pharmaceutical sector faces turbulence from proposed US tariffs, Bayer's leadership has projected confidence by reaffirming its financial targets. This stance comes as a major Wall Street firm quietly adjusted its stake in the company.

Shareholder Adjustment and Market Performance

A notable shift occurred in Bayer's shareholder registry. Investment bank Goldman Sachs reduced its voting rights stake from 5.24% to 4.44%, moving below a key regulatory disclosure threshold. This reduction was primarily in derivative instruments, with direct voting rights remaining largely unchanged. The market response to this mixed news flow has been measured. On Tuesday, Bayer shares closed at €39.27. This price sits approximately 6% below the closely watched 50-day moving average, yet the stock maintains a significant upward trajectory over a twelve-month period.

Core Forecasts Unchanged by Trade Policy

The focal point of industry concern is the threat of 100% US tariffs on patented pharmaceuticals. Bayer's management, specifically board member Sebastian Guth, has clarified that this trade policy development does not necessitate a revision to the company's guidance. This confidence stems from existing trade agreements that guarantee a strict tariff ceiling of 15% for products originating from the European Union.

According to company executives, these potential cost implications were already factored into forward-looking calculations. Consequently, the conglomerate continues to target an EBITDA before special items ranging between €9.6 billion and €10.1 billion for 2026. Market analysts view this operational stability positively. The current average price target among experts stands at €46.53, accompanied by a predominant recommendation for investors to increase their existing holdings.

Strategic Positioning Ahead of Implementation

By clearly confirming its EBITDA objectives, Bayer's management has proactively addressed geopolitical anxieties. The operational execution of this strategy now forms the immediate benchmark for upcoming quarterly results. This period of scrutiny will precede the official enactment of the new US tariffs, scheduled for September. The company's firm guidance aims to demonstrate resilience and strategic planning in the face of external trade pressures.